Kairos Pharma Initiates Phase 1 Trial of ENV105 Combo for EGFR-Driven Lung Cancer

Kairos Pharma, a biopharmaceutical firm in the clinical stage, has embarked on a Phase 1 trial to test a novel combination treatment for non-small cell lung cancer (NSCLC). The trial involves the use of their lead candidate, ENV105, alongside osimertinib, a medication typically used to combat EGFR-mutated lung cancers. The company's CEO, John Yu, highlighted the significance of the trial, emphasizing the team's commitment to addressing unmet medical needs.

The trial is designed to assess the safety and tolerability of the combined treatment, targeting 60 patients who have shown resistance to osimertinib or have partial sensitivity to it. Kairos Pharma's Chief Scientific Officer, Dr. Neil Bhowmick, explained the rationale behind using ENV105, a first-in-class biologic, to enhance the responsiveness of EGFR-driven lung cancer to EGFR-antagonists like osimertinib, which patients often develop resistance to over time.

Headquartered in Los Angeles, California, Kairos Pharma is dedicated to advancing a pipeline of oncology therapeutics aimed at overcoming the immune system's inhibitory effects caused by cancer. The company's innovative drug candidates are specifically designed to counteract resistance and immune suppression in cancer treatment.